Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes

Drug Metabolism and Disposition

Volumn 34, Issue 4, 2006, Pages 702-708

  Lu, Chuang ^a   Gallegos, Richard ^a   Li, Ping ^a   Xia, Cindy Q ^a   Pusalkar, Sandeepraj ^a   Uttamsingh, Vinita ^a   Nix, Darrell ^a   Miwa, Gerald T ^a   Gan, Liang Shang ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; CYTOCHROME P450 4A; PALMITOYL COENZYME A;

ANIMAL CELL; ARTICLE; DEALKYLATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME METABOLISM; FEMALE; IC 50; LIVER MICROSOME; METABOLITE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; ORGAN SIZE; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 33645104020     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008060     Document Type: Article

References (26)

1. Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28:613-619.
2. Berenson JR, Ma HM, and Vescio R (2001) The role of nuclear factor-κB in the biology and treatment of multiple myeloma. Semin Oncol 28:626-633.
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469.
4. Carlile DJ, Hakooz N, and Houston JB (1999) Kinetics of drug metabolism in rat liver slice: IV. Comparison of ethoxycoumarin clearance by liver slice, isolated hepatocytes and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity. Drug Metab Dispos 27:526-532.
5. Chauhan D, Hideshima T, and Anderson KC (2005) Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45:465-476.
6. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79:13-21.
7. Correia MA, Sadeghi S, and Mundo-Paredes E (2005) Cytochrome P450 ubiquitination: branding for the proteolytic slaughter? Annu Rev Pharmacol Toxicol 45:439-464.
8. Garg A and Aggarwal BB (2002) Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 6:1053-1068.
9. Guengerich FP (1989) Analysis and characterization of enzymes, in Principles and Methods of Toxicology (Hayes AW ed) pp 777-813, Raven Press, New York.
10. Huber WW, Grasl-Kraupp B, Stekel H, Gschwentner C, Lang H, and Schulte-Hermann R (1997) Inhibition instead of enhancement of lipid peroxidation by pretreatment with the carcinogenic peroxisome proliferator nafenopin in rat liver exposed to a high single dose of corn oil. Arch Toxicol 9:575-581.
11. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
12. Kitz R and Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-3249.
13. Kuerbitz SJ, Plunkett BS, Walsh WV, and Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495.
14. Kwon Y (2001) Metabolism, in Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists (Kwon Y ed) pp 121-168, Kluwer Academic/Plenum, New York.
15. Lazarow PB (1981) Assay of peroxisomal β-oxidation of fatty acid. Methods Enzymol 72:315-319.
16. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 7:2370-2378.
17. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott P, et al. (1998) Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95:15671-15676.
18. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, and Miwa G (2005) Human metabolism of the proteasome inhibitor Bortezomib: Identification of circulating metabolites. Drug Metab Dispos 33:771-777.
19. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617.
20. Roberts B (1997) Evidence of proteasome-mediated cytochrome P-450 degradation. J Biol Chem 272:9771-9778.
21. Small GM, Burdett K, and Connock MJ (1985) A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase. Biochem J 227:205-210.
22. Stinchcombe TE, Mitchell BS, Depcik-Smith N, et al. (2000) PS-341 is active in multiple myeloma: a preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies (Abstract). Blood 96:516a.
23. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transport interaction potential-toward a consensus. Pharm Res (NY) 18:1071-1075.
24. Uttamsingh V, Lu C, Miwa G, and Gan LS (2005) Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6 and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 33:1723-1728.
25. Wu S, Waugh W, and Stella VJ (2000) Degradation pathway of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)2. J Pharm Sci 89:758-765.
26. Zangar RC, Kocarek TA, Shen S, Bollinger N, Dahn MS, and Lee DW (2003) Suppression of cytochrome P4503A protein levels by proteasome inhibitors. J Pharmacol Exp Ther 305:872-879.